Epigenetic therapy as a novel approach in hepatocellular carcinoma

Ioannis Anestopoulos, Georgia Persephoni Voulgaridou, Alexandros G. Georgakilas, Rodrigo Franco, Aglaia Pappa, Mihalis I. Panayiotidis

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


Hepatocellular carcinoma (HCC) is the most common type of liver malignancy and one with high fatality. Its 5-year survival rate remains low and thus, there is a need for improvement of current treatment strategies as well as development of novel targeted methodologies in order to optimize existing therapeutic protocols. To this end, only recently, it was discovered that its pathophysiology also involves epigenetic alterations in DNA methylation, histone modifications and/or non-coding microRNA patterns. Unlike genetic events, epigenetic alterations are reversible and thus potentially considered to be an alternative option in cancer treatment protocols. In this review, we describe the general characteristics and resulted major alterations of the epigenetic machinery as well as current state of progress of epigenetic therapy (via different single or combinatorial experimental approaches) in HCC.

Original languageEnglish (US)
Pages (from-to)103-119
Number of pages17
JournalPharmacology and Therapeutics
StatePublished - Jan 2015


  • DNMT inhibitors
  • Epigenetic modifications
  • Epigenetic therapy
  • HDAC inhibitors
  • Hepatocellular carcinoma
  • Natural products

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Epigenetic therapy as a novel approach in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this